LYFNUA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania, Spain.

Active ingredients

The drug LYFNUA contains one active pharmaceutical ingredient (API):

1	Gefapixant UNII DFK0FC2VVV - GEFAPIXANT CITRATE
	Gefapixant is a selective antagonist of the P2X3 receptor. P2X3 receptors are ATP-gated ion channels found on sensory C fibres of the vagus nerve in the airways. C fibres are activated in response to inflammation or chemical irritants. Blockade of ATP signalling through P2X3 receptors reduces excessive sensory-nerve activation and excessive cough induced by extracellular ATP.
	Read more about Gefapixant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYFNUA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R05DB29		R Respiratory system → R05 Cough and cold preparations → R05D Cough suppressants, excl. combinations with expectorants → R05DB Other cough suppressants
Discover more medicines within R05DB29

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3046328, 3046339, 3046340, 3046351
ES	Centro de información online de medicamentos de la AEMPS	1211613002
FR	Base de données publique des médicaments	68546447
IT	Agenzia del Farmaco	050897014, 050897026, 050897038, 050897040
JP	医薬品医療機器総合機構	2290001F1028
LT	Valstybinė vaistų kontrolės tarnyba	1097792, 1097793, 1097794, 1097795